report adjust ep
consensu expect lower estim higher-than-
expect adjust oper expens account downsid
rel forecast believ better-than-anticip revenu drove
upsid adjust ep rel consensu
zbh revenu increas year-over-year million
consensu expect million slightli
higher million estim quarter compani
organ growth posit forecast notabl rebat
adjust emea region posit surpris quarter
ad roughli million year-over-year zbh revenu
product standpoint better-than-anticip perform zbh
product divis craniomaxillofaci cmf portion zbh spine
cmf busi drove upsid rel revenu estim help
off-set weaker-than-expect america knee implant sale
zbh adjust oper margin declin bp year-over-year
forecast primarili reflect increment
invest intend turn around organ growth perform
provid guidanc larg consist prior consensu
expect well previou comment sell-sid healthcar
confer earn call specif expect
adjust ep versu prior consensu expect
organ growth versu adjust
oper margin versu notabl compani
guidanc continu assum million reduct quarterli revenu
result loss bone cement distribut
agreement heraeu medic palaco well improv
perform key knee product launch persona cementless knee
persona revis knee rosa total knee applic reach gener releas
rais adjust ep estim reflect
lower tax interest expens assumpt off-set slightli
total debt total asset
expect low head earn call given
compani prior comment expect south organ growth well
contract adjust oper margin given backdrop compani
guidanc bad fear expect execut
issu zbh persona cementless revis knee launch question
remain rosa knee applic stack versu mako
focu knee launch impact hip busi rate remain
import pleas read disclosur disclaim page report
report adjust ep consensu expect lower
estim higher-than-expect adjust oper expens account downsid rel
forecast believ better-than-anticip revenu drove upsid adjust ep rel
zbh revenu increas year-over-year million consensu expect
million slightli higher million estim quarter compani organ
growth posit forecast currenc chang reduc revenu growth
year-over-year notabl rebat adjust emea region posit surpris quarter
ad roughli million year-over-year zbh revenu
adjust incom statement analysisnorthcoast research million except percent per share sg interest expens interest expens incom incom incom margin com share compani report northcoast research estim factset
product categori standpoint better-than-anticip perform zbh product divis
craniomaxillofaci cmf portion zbh spine cmf busi drove upsid rel revenu
estim help off-set weaker-than-expect america knee implant sale product zbh bone
cement sale declin million rang year-over-year due loss palaco distribut
agreement howev remain product categori segment particularli strong lead
million year-over-year declin product revenu addit organ growth zbh spine busi
neg combin spine cmf divis grew organ led strong revenu rosa robot
brain applic
knee post organ growth posit estim quarter
knee implant market growth appear modestli weaker anticip posit rang tough
year-over-year comparison zbh market share loss appear steadi bp year-over-year versu
similar perform first nine month year geograph standpoint zbh asia pacif knee
inc organ growth analysi reflect pro forma result zimmer biomet compani report northcoast organ growth analysisnorthcoast currenc constant currenc acquisit divestitur organ hip knee spine cmf dental compani report northcoast research estim busi except strong year-over-year america knee segment
weaker expect neg reflect soft market
compani knee implant price growth also rel steadi quarter year-over-year versu
year-over-year reduct
continu believ product suppli product gap drive modest market share loss knee
regard product gap compani obtain regulatori clearanc persona cementless knee
persona revis knee rosa total knee applic expect product limit
releas enter full releas particular expect new knee offer help
compani product mix standpoint given price premium cementless knee robot
increment consum revenu per procedur revis knee roughli price point
primari knee less price pressur said given time full launch product
zbh knee implant busi like continu grow market rate anoth quarter even
address suppli issu complet product launch in-lin forecast
hip post posit organ growth consist forecast similar knee
hip market growth appear littl softer sequenti posit rang year-over-year zbh
growth slightli market rate three quarter modest market share gain primari differ
versu prior quarter zbh hip busi slowdown asia pacif organ
compani face difficult year-over-year comparison year-over-year contrast
compani hip result posit emea organ america organ easi
emea comp neg aid perform addit price growth hip improv
quarter year-over-year versu year-over-year declin although appear
primarili reflect rebat adjust emea repeat subsequ quarter
inc knee organ growth analysi reflect pro forma result zimmer biometsourc compani report northcoast
zbh adjust oper margin declin bp year-over-year
forecast quarter adjust gross margin bp estim bp year-over-year
includ impact neg price growth adjust oper expens higher
anticip specif adjust sg expens increas bp percent sale primarili
reflect increment invest area includ sale forc effort turn around organ growth
perform addit expens modestli model million versu
provid guidanc larg consist prior consensu expect well previou
comment sell-sid healthcar confer earn call specif expect
adjust ep versu prior consensu expect organ growth
versu adjust oper margin versu notabl
compani guidanc continu assum million reduct quarterli revenu
result loss bone cement distribut agreement heraeu medic palaco well
inc hip organ growth analysi reflect pro forma result zimmer biomet compani report northcoast inc quarterli total compani price growth year-over-year compani improv perform key knee product launch persona cementless knee persona revis knee
rosa total knee applic reach gener releas
rais adjust ep estim reflect lower tax interest expens
assumpt off-set slightli lower adjust oper incom forecast new
adjust ep estim
overal expect low head earn call given compani prior
comment expect south organ growth well contract adjust oper margin
given backdrop compani guidanc bad fear expect execut
issu zbh persona cementless revis knee launch question remain rosa knee
applic stack versu mako focu knee launch impact hip busi rate
guidanc performancerevenu growth yr/yr currenc growth yr/yr constant currenc growth yr/yr organ growth yr/yr acquisit growth oper interest expens tax ep growth yr/yr compani report northcoast research estim would millionexclud one-tim payment million relat patent litig matter
inc annual incom statement analysi adjust northcoast research million except percentag per share gross gross sg sg oper oper net interest incom net interest incom incom incom incom tax minor incom extra incom extra extra net net wghd com share ep ep growth ep growth compani report northcoast research estim disclosur
